Sartorius Stedim Biotech (OTCMKTS:SDMHF – Get Free Report) is expected to be posting its resultson Thursday, July 23rd. Analysts expect Sartorius Stedim Biotech to post earnings of $1.44 per share and revenue of $906.42 million for the quarter.
Sartorius Stedim Biotech Stock Performance
Shares of SDMHF stock opened at $215.50 on Tuesday. Sartorius Stedim Biotech has a fifty-two week low of $178.30 and a fifty-two week high of $264.30. The company has a 50 day moving average price of $201.37 and a 200 day moving average price of $208.99.
Sartorius Stedim Biotech Company Profile
Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.
Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.
Recommended Stories
- Five stocks we like better than Sartorius Stedim Biotech
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Sartorius Stedim Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Stedim Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
